SPOTLIGHT -
EP. 1: Deciding on Adjuvant Therapy in CRC
EP. 2: Duration of Adjuvant Therapy: CRC Subsets
EP. 3: Managing Patients After Adjuvant Therapy
EP. 4: Treating Liver or Peritoneal Metastases in CRC
EP. 5: Early-Onset CRC: What Do We Know?
EP. 6: Role of Molecular Testing in CRC Management
EP. 7: Importance of HER2 Expression in CRC
EP. 8: Left- Versus Right-Sided Tumors in CRC
EP. 9: Frontline Antibody Selection in Metastatic CRC
EP. 10: Maintenance and Second-Line Decisions in CRC
EP. 11: Supportive Care in Metastatic CRC
EP. 12: Immunotherapy Options in Refractory CRC
EP. 13: Third-Line Treatment in Refractory CRC
EP. 14: Dosing and Side Effect Management in Metastatic CRC
EP. 15: Managing Toxicities With Immunotherapy in CRC
EP. 16: Emerging Immunotherapy Combinations in MSS CRC
EP. 17: Progress in CRC Precision Medicine
EP. 18: Improving Outcomes in CRC
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
